Hillhouse Capital plans to invest USD 1 billion in the Chinese biotechnology company BeiGene
. Acting as the anchor investor, Hillhouse participants in this USD 2.1 billion direct offering of 145.8 million ordinary shares. This financing is jointly participated by existing shareholders and major investors of BeiGene.
After completing the transaction, all investors participating in this transaction will hold a share of approximately 65.81%. And this share sale will also be the most significant equity financing in the global biotech sector.